{
    "organizations": [],
    "uuid": "d2e060e76a032dc8050db6c28eed4b94912c1d4d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunogen-completes-interim-analys/brief-immunogen-completes-interim-analysis-for-forward-i-phase-3-trial-of-mirvetuximab-soravtansine-idUSASC09XU6",
    "ord_in_thread": 0,
    "title": "Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - ImmunoGen Inc:\n* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER\n* IMMUNOGEN INC - FORWARD I TRIAL HAS COMPLETED FULL ENROLLOMENT; TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019 Source text for Eikon:\n ",
    "published": "2018-04-27T04:42:00.000+03:00",
    "crawled": "2018-04-27T16:16:05.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "immunogen",
        "inc",
        "immunogen",
        "announces",
        "successful",
        "completion",
        "interim",
        "analysis",
        "forward",
        "phase",
        "trial",
        "mirvetuximab",
        "soravtansine",
        "ovarian",
        "cancer",
        "immunogen",
        "inc",
        "forward",
        "trial",
        "completed",
        "full",
        "enrolloment",
        "result",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "eikon"
    ]
}